DXCM Quantitative Stock Analysis

Validea's guru fundamental report indicates that DEXCOM INC (DXCM) receives a 77% rating based on their P/B Growth Investor model, which is based on the strategy of Partha Mohanram. The model, which favors low book-to-market stocks exhibiting sustained growth characteristics, positively assesses DXCM's book/market ratio, return on assets, cash flow, and sales variance, but flags the company for its capital expenditures and research & development relative to assets. Mohanram's research focuses on identifying growth stocks that maintain upward trajectories using financial statement analysis.

Analysis

DexCom Inc. (DXCM), a large-cap stock in the Medical Equipment & Supplies industry, has been evaluated by Validea's P/B Growth Investor model, which is derived from Partha Mohanram's academic research on identifying growth stocks with sustained upward trajectories. DXCM achieved a 77% rating on this model, which focuses on low book-to-market stocks; this score is marginally below the 80% threshold that typically signals strategy interest. The company demonstrated strength by passing criteria related to its book/market ratio, return on assets, cash flow from operations relative to assets, consistency in return on assets and sales variance, and advertising expenditure relative to assets. However, DXCM received a "FAIL" on metrics for capital expenditures to assets and research and development to assets. Within the context of Mohanram's growth-focused strategy, these failures likely suggest that the company's investment levels in these key areas for future innovation and expansion are perceived by the model as potentially insufficient for a stock expected to maintain a strong growth trajectory.

Key Decisions for Investors

• Investors should view DXCM's 77% rating on the Partha Mohanram P/B Growth model as indicative of several strong fundamental growth characteristics, such as good profitability and cash flow, while noting this score is slightly below the model's 80% threshold for distinct interest.
• It is crucial to further analyze DXCM's capital expenditure and research & development spending relative to its assets, as the model's "FAIL" designation suggests these investment levels might be considered suboptimal for sustaining long-term growth according to this specific quantitative strategy.
• Portfolio managers should weigh the positive financial metrics against the model's concerns regarding DXCM's investment in future growth drivers (CapEx and R&D), considering this alongside the company's overall strategic direction and position within the Medical Equipment & Supplies industry.